Table 3 Examples of existing and novel non-oral dopaminergic delivery forms
Non-oral therapies | Examples | Status |
|---|---|---|
L-dopa | ||
Intraduodenal infusion | DuoDopa | Marketed |
Subcutaneous infusion | ND0612L | Clinical trials |
Inhalation | CVT-301 | Clinical trials |
Apomorphine | ||
Subcutaneous injection | APO-go pen | Marketed |
Subcutaneous infusion | APO-go PFS | Marketed |
Inhalation | - | Clinical trials |
Intranasal | - | Clinical trials |
Sublingual | APL-130277 | Clinical trials |
DA agonists | ||
Rotigotine transdermal | NeuPro | Marketed |
Rotigotine subcutaneous depot | LY03003 | Clinical trials |
Bromocriptine intranasal | - | Experimental |